SUMMARY The outcome of attempts to continue treatment indefinitely with either gold, penicillamine, sulphasalazine, or dapsone was studied in 240 patients with rheumatoid arthritis (RA). The usual reason for discontinuing treatment was the occurrence of an adverse effect. This led to 53% of patients stopping gold, 33% sulphasalazine, 32% penicillamine, and 17% dapsone. The next most frequent reason was that the drug was ineffective, leading to discontinuation in 37% of patients havingdapsone, 24% sulphasalazine, 19% pencillamine, and 16% gold. Otherreasonsfor stopping treatment were infrequent. The high discontinuation rate of these drugs over 2 years in part accounts for the conflict of opinion on whether they can alter the course of RA; their efficacy must to a large extent be governed by their acceptibility.
In rheumatoid arthritis (RA) the effects of 'remission-inducing drugs' (RIDs) have often been studied over periods of 6 to 12 months. In this time some drugs, notably gold' and penicillamine,2 influence the disease favourably. Less The reasons for treatment termination were different for each of the four drugs.
GOLD
The commonest reason for discontinuing gold (Table  3) was toxicity in 39 patients (53%). Rash was the most frequent adverse reaction and, like most other unwanted effects, usually occurred within the first 12 months. Eight patients had proteinuria and 3 throm- Eight patients (19%) discontinued penicillamine within 2 years because they were no better and 3 patients (7%) because of a relapse of their disease.
SU LPHASALAZINE
The commonest reason for discontinuing treatment was an adverse effect in 40 (33%) patients. The most frequent problems were nausea, malaise, dyspepsia, and dizziness, usually occurring in the first 2 months of treatment; only 2 patients discontinued SAS for these reasons after 6 months. Five patients had a rash, and one patient had neutropenia but recovered within 6 weeks.
Inadequate benefit in 29 patients (24%) was the next most frequent reason for discontinuation. Fourteen patients (11 %) stopped treatment because their falls in haemoglobin, was a contributory factor in 6 patients.
Discussion
The criteria for treatment with each drug were the same.5 Thus we expected the groups of patients to be comparable, and they matched in many respects. However, the mean ESR and serum CRP before treatment suggest we had inadvertently selected patients with more active disease for treatment with gold or penicillamine. We cannot say how much these initial differences might have influenced the results. More active disease might be more resistant to treatment but, conversely, may have a greater capacity for improvement.
When all treatments are considered together the results are discouraging. Despite our intention to continue each drug indefinitely so long as clinical and laboratory evidence suggested it was beneficial, only about half the patients were still receiving their drug at a year and a fifth at 2 years.
The principal problems were adverse effects in a third of patients taking penicillamine or SAS and in half of those taking gold. Dapsone differed from the other 3 drugs in that adverse effects were less important, and failure to derive benefit was the main reason for discontinuing treatment. With so few patients able to continue treatment for periods exceeding a year it is not surprising that difficulty has been encountered in proving these drugs have a disease modifying effect.
Could the performances of these drugs be improved? We doubt from our more recent experience6 whether the performance of penicillamine could have 
